[PDF][PDF] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

RH Collins Jr, O Shpilberg, WR Drobyski… - Journal of clinical …, 1997 - researchgate.net
RH Collins Jr, O Shpilberg, WR Drobyski, DL Porter, S Giralt, R Champlin, SA Goodman…
Journal of clinical oncology, 1997researchgate.net
Purpose: Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may
attain complete remissions when treated with transfusions of leukocytes obtained from the
original bone marrow donor. We performed a retrospective study to characterize better this
new treatment modality. Patients and Methods: We surveyed 25 North Ameri-can BMT
programs regarding their use of donor leukocyte infusions (DLI). Detailed forms were used
to gather data regarding the original BMT, relapse, DLI, response to DLI, complications of …
Purpose: Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may attain complete remissions when treated with transfusions of leukocytes obtained from the original bone marrow donor. We performed a retrospective study to characterize better this new treatment modality.
Patients and Methods: We surveyed 25 North Ameri-can BMT programs regarding their use of donor leukocyte infusions (DLI). Detailed forms were used to gather data regarding the original BMT, relapse, DLI, response to DLI, complications of DLI, and long-term follow-up evaluation. Reports of 140 patients were thus available for analysis.
Results: Complete responses were observed in 60%(95% confidence interval [Cl], 51.9% to 68.1%) of chronic myelogenous leukemia (CML) patients who received DLI and did not receive pre-DLI chemotherapy; response rates were higher in patients with cytogenetic and chronic-phase relapse (75.7%; 95% Cl, 68.2% to 83.2%) than in patients with accelerated-phase (33.3%; 95% Cl, 19.7% to 46.9%) or blastic-phase (16.7%; 95% Cl, 1.9% to 31.9%) relapse. The actuarial probability of remaining in complete remission at 2 years was 89.6%. Complete remission rates in acute myelogenous leukemia (AML)(n
researchgate.net